Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan Fowler

Showing results (51-60 of 87) with videos related to

Pageof 9
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|January 2, 2013
Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trialJason R Westin, Michael A Thompson, Vince D Cataldo, et al.
Cancer Discovery|February 5, 2021
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental SignaturesNikita Kotlov, Alexander Bagaev, Maria V Revuelta, et al.
Advances in Radiation Oncology|October 30, 2018
Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapyTommy Sheu, Sarah A Milgrom, Therese Y Andraos, et al.
Biorxiv : the Preprint Server for Biology|February 8, 2024
Integrative genomic analysis identifies unique immune environments associated with immunotherapy response in diffuse large B cell lymphomaSravya Tumuluru, James K Godfrey, Alan Cooper, et al.
British Journal of Haematology|September 4, 2018
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinibPreetesh Jain, Rashmi Kanagal-Shamanna, Shaojun Zhang, et al.
Head & Neck|April 4, 2017
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphomaChelsea C Pinnix, Bouthaina S Dabaja, Sarah A Milgrom, et al.
The Lancet. Oncology|December 17, 2013
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trialJason R Westin, Fuliang Chu, Min Zhang, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trialYasuhiro Oki, Michael S Ewer, Daniel J Lenihan, et al.
Communications Biology|March 30, 2024
Procrustes is a machine-learning approach that removes cross-platform batch effects from clinical RNA sequencing dataNikita Kotlov, Kirill Shaposhnikov, Cagdas Tazearslan, et al.
Blood|January 27, 2025
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody responseSravya Tumuluru, James K Godfrey, Alan Cooper, et al.
Pageof 9

Showing results (51-60 of 87) with videos related to

Sort By:
Pageof 9
Clinical Lymphoma, Myeloma & Leukemia|January 2, 2013
Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trialJason R Westin, Michael A Thompson, Vince D Cataldo, et al.
Cancer Discovery|February 5, 2021
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental SignaturesNikita Kotlov, Alexander Bagaev, Maria V Revuelta, et al.
Advances in Radiation Oncology|October 30, 2018
Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapyTommy Sheu, Sarah A Milgrom, Therese Y Andraos, et al.
Biorxiv : the Preprint Server for Biology|February 8, 2024
Integrative genomic analysis identifies unique immune environments associated with immunotherapy response in diffuse large B cell lymphomaSravya Tumuluru, James K Godfrey, Alan Cooper, et al.
British Journal of Haematology|September 4, 2018
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinibPreetesh Jain, Rashmi Kanagal-Shamanna, Shaojun Zhang, et al.
Head & Neck|April 4, 2017
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphomaChelsea C Pinnix, Bouthaina S Dabaja, Sarah A Milgrom, et al.
The Lancet. Oncology|December 17, 2013
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trialJason R Westin, Fuliang Chu, Min Zhang, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2014
Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trialYasuhiro Oki, Michael S Ewer, Daniel J Lenihan, et al.
Communications Biology|March 30, 2024
Procrustes is a machine-learning approach that removes cross-platform batch effects from clinical RNA sequencing dataNikita Kotlov, Kirill Shaposhnikov, Cagdas Tazearslan, et al.
Blood|January 27, 2025
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody responseSravya Tumuluru, James K Godfrey, Alan Cooper, et al.
Pageof 9